Cargando…

The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma

BACKGROUND/AIMS: Relatively little data are available on how the response to the coronavirus disease 2019 (COVID-19) pandemic has affected treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. We aimed to determine the effect of COVID-19 countermeasures on treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Ka-Won, Lee, Byung-Hyun, Jeon, Min Ji, Yu, Eun Sang, Kim, Dae Sik, Lee, Se Ryeon, Sung, Hwa Jung, Choi, Chul Won, Park, Yong, Kim, Byung Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Internal Medicine 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588990/ https://www.ncbi.nlm.nih.gov/pubmed/34666434 http://dx.doi.org/10.3904/kjim.2021.186

Ejemplares similares

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2022)

Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma
por: Kang, Ka-Won, et al.
Publicado: (2018)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
por: Kang, Ka‐Won, et al.
Publicado: (2020)

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
por: Kang, Ka-Won, et al.
Publicado: (2020)

Prognostic outcomes of cytomegalovirus reactivation after autologous stem cell transplantation
por: Lee, Byung-Hyun, et al.
Publicado: (2023)

Cytomegalovirus reactivation under pre-emptive therapy following allogeneic hematopoietic stem cell transplant: Pattern, survival, and risk factors in the Republic of Korea
por: Kang, Ka-Won, et al.
Publicado: (2023)

Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia
por: Jeon, Min Ji, et al.
Publicado: (2020)

The role of platelet function analyzer-200 in predicting perioperative bleeding risk
por: Yu, Eun Sang, et al.
Publicado: (2020)

A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
por: Kang, Ka-Won, et al.
Publicado: (2021)

Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
por: Lee, Byung-Hyun, et al.
Publicado: (2020)

Postoperative Thromboembolism According to the Type of Surgery: A Nationwide Study in the Republic of Korea
por: Kang, Ka-Won, et al.
Publicado: (2022)

BK virus encephalitis without concurrent hemorrhagic cystitis in an allogeneic hematopoietic stem cell transplant recipient
por: Lee, Suk-young, et al.
Publicado: (2013)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

A Case of Coincident Multiple Myeloma and Non-Hodgkin’s Lymphoma
por: Lee, Geun Chan, et al.
Publicado: (1994)

Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
por: Shin, Junghoon, et al.
Publicado: (2017)

Newly Developed Multiple Myeloma in a Patient with Primary T-Cell Lymphoma of Bone
por: Hwang, Jun-Eul, et al.
Publicado: (2008)

PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model
por: Lee, Byung-Hyun, et al.
Publicado: (2020)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
por: Kang, Byung Woog, et al.
Publicado: (2014)

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011)

Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
por: Jeon, Min Ji, et al.
Publicado: (2023)

Diffuse Infiltrative Primary Cardiac Lymphoma with Delayed Extracardiac Involvement
por: Jeoung, Yong, et al.
Publicado: (2014)

A Novel Anti-PD-L1 Antibody Exhibits Antitumor Effects on Multiple Myeloma in Murine Models via Antibody-Dependent Cellular Cytotoxicity
por: Ahn, Jae-Hee, et al.
Publicado: (2021)

Successful treatment of disseminated interdigitating dendritic cell sarcoma with adriamycin, bleomycin, vinblastine, and dacarbazine chemotherapy
por: Lee, Suk-young, et al.
Publicado: (2012)

Unusual Presentation of Multiple Myeloma
por: Jeon, Jeong Suk, et al.
Publicado: (2018)

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
por: Batsukh, Khishigjargal, et al.
Publicado: (2017)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
por: Cho, Hee Jeong, et al.
Publicado: (2023)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
por: Cho, Hee Jeong, et al.
Publicado: (2023)

The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma
por: Min, Chang-Ki, et al.
Publicado: (2013)

Persistent Anemia in a Patient with Diffuse Large B Cell Lymphoma: Pure Red Cell Aplasia Associated with Latent Epstein-Barr Virus Infection in Bone Marrow
por: Sung, Hwa Jung, et al.
Publicado: (2007)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

A case of synchronous multiple myeloma and chronic myeloid leukemia
por: Lee, Ji-Young, et al.
Publicado: (2017)

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
por: Kim, Min Kyoung, et al.
Publicado: (2017)

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)
por: Lee, Ho Sup, et al.
Publicado: (2020)

Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
por: Cho, Hee-Jeong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g7p9nt72d4n4pc76meb4efecfd